Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 98,343,956 | 105,993,785 | 68,998,263 | 56,092,197 | 71,750,648 | 401,178,849 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 98,343,956 | 105,993,785 | 68,998,263 | 56,092,197 | 71,750,648 | 401,178,849 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 119,793,612 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 281,385,237 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 98,343,956 | 105,993,785 | 68,998,263 | 56,092,197 | 71,750,648 | 401,178,849 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 1,722,957 | 1,346,882 | 2,204,173 | 4,421,167 | 5,005,462 | 14,700,641 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | 0 | 0 | 0 | 760,596 | 760,596 |
| 11 | Total support. Add lines 7 through 10 | 416,640,086 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2024 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2024 |
(iii) Distributable Amount for 2024 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2024 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2024 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2024: | ||||
| a From 2019....... | ||||
| b From 2020....... | ||||
| c From 2021....... | ||||
| d From 2022....... | ||||
| e From 2023....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2024 distributable amount | ||||
|
i
Carryover from 2019 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2024 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2024 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2024, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2024. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2025. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2020..... | ||||
| b Excess from 2021..... | ||||
| c Excess from 2022..... | ||||
| d Excess from 2023..... | ||||
| e Excess from 2024..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| Schedule A, Part II, Line 10 Other Income | DESCRIPTION - FUNDRAISING REVENUE, COLUMN A - , COLUMN B - , COLUMN C - , COLUMN D - , COLUMN E - 760596.0, COLUMN F - 760596.0; |
| Software ID: | 24020961 |
| Software Version: | 2024v5.1 |
| Return Reference | Explanation |
|---|---|
| Form 990, Part I, Line 1 Brief Mission | To create and lead alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. |
| Form 990, Part III, Line 4a Program Service Description | PROGRAM ONE - RESEARCH PROGRAMS - ACCELERATING MEDICINES PARTNERSHIP PROGRAM The FNIH manages the Accelerating Medicines Partnership (AMP) program with the interests of the collective scientific and medical research communities in mind. Its mission is to improve understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate new and effective therapies to patients. All AMP projects operate under the broad principle of delivering pre-competitive advancements to the research and medical fields and enabling the broadest possible access and use of AMP research discoveries. A critical component of each public-private partnership in the AMP program is an agreement among partners to make data and analyses arising from the collaboration publicly accessible to benefit the broader biomedical community. Individual AMP projects frequently establish public portals to rapidly disseminate data from their research efforts, and AMP-funded publications are required to be made available publicly within specific timeframes. At the center of the AMP program is a common goal of accelerating new and effective therapies to patients. AMP projects work towards this goal by identifying clinically relevant disease targets, improving identification of patients most likely to respond to a particular treatment, and safely reducing the development timelines for life-saving therapies and improvements in patient outcomes. The AMP program celebrated its 10-year anniversary in 2024 with a two-day symposium spotlighting the wide-ranging impact of the initiative. BIOMARKERS CONSORTIUM The Biomarkers Consortium (BC) creates and leads cross-sector efforts that validate and qualify biomarkers and other tools to accelerate better decision making for the development of new therapeutics and health technologies. It convenes government, industry, patients and patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogate endpoints. The BC is helping facilitate, catalyze, and support a new era of precision medicine by advancing biomarker science to enable earlier interventions, personalized treatments, and better outcomes in disease prevention, detection, diagnosis, and therapy. GENECONVENE GLOBAL COLLABORATIVE The GeneConvene Global Collaborative continues to advance best practices and support informed decision-making on the scientific, regulatory, and policy questions raised by the development of genetic biocontrol technologies to control the spread of malaria and other mosquito-borne diseases. GeneConvene convened in 2024 a working group of developers preparing for field trials to assess technologies for entomological monitoring and surveillance, hosting a webinar and meeting on environmental monitoring, and leading a Gene Drive Research Forum discussion of the opportunities for ecological modeling to further contribute to safety assessments. Through the African Genetic Biocontrol Consortium, the program also conducted two workshops for scientists and science communicators to build relationships and skills. GeneConvene also strengthened biosafety regulatory capacity through a training conducted with the African Union Development Agency-NEPAD and sponsored a course for 50 faculty and PhD-level scientists from African institutions on genome editing. RESEARCH PROGRAMS FOR ACCELERATING NEW THERAPIES RESEARCHING COVID TO ENHANCE RECOVERY-TREATING LONG COVID (RECOVER-TLC) RECOVER-TLC is a partnership between the NIH's National Institute of Allergy and Infectious Diseases and the FNIH, with the overarching goal to launch additional Long COVID clinical trials with promising agents. Therapeutic submissions were submitted to the online portal in 2024, and a process was created to enable uniform assessment of all submitted agents. These efforts initiated early working group formation, with the Antiviral Working Group conducting initial agent review by the end of 2024. NEW AMP PROJECTS AMP AMYOTROPHIC LATERAL SCLEROSIS (ALS) AMP ALS was launched in 2024 to expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for ALS, a progressive and ultimately fatal neurological disease. The project will create the largest data source for ALS research. AMP PARKINSON'S DISEASE AND RELATED DISORDERS (PDRD) AMP PDRD, launched in 2024, seeks to employ a data-driven approach to identify and validate biomarkers distinguishing Parkinson's disease from related diseases, with an overarching goal to enhance the success of clinical trials and ultimately broaden treatment options for individuals affected by these conditions. BIOMARKERS CONSORTIUM RESEARCH PROJECTS EARLY DETECTION OF ALZHEIMER'S DISEASE: PLASMA A Results of a Plasma A project study on early diagnosis of Alzheimer's disease were published last year. This head-to-head evaluation and cross-platform validation of biomarkers that most accurately detect amyloid plaques and other Alzheimer's-related pathologies revealed that the performance of some blood plasma tests were as good as cerebrospinal fluid tests. This finding suggested that simple blood tests could replace invasive spinal taps or costly brain scans for many patients. The study confirmed that blood tests are an accessible, less invasive, and highly accurate method of detecting amyloid plaques. The study offered further confirmation that blood tests measuring levels of the protein p-tau217 are the most accurate in determining the presence and amount of amyloid plaques. Alzheimer's blood tests could speed future drug development by helping researchers select the optimal participants for clinical trials. NEUROFILAMENT AS A BLOOD-BASED BIOMARKER OF NEURODEGENERATION IN FAMILIAL FTD The earliest stages of frontotemporal dementia (FTD) are hard to detect until the disease has progressed and damage is permanent. This project seeks to identify reliable blood tests to detect FTD and give access to disease-modifying clinical trials. The FDA accepted a Letter of Intent to qualify neurofilament (a key protein component of neurons) as a biological indicator of FTD in April 2024. This biomarker qualification initiative is crucial for improving the ability to identify individuals at high risk of progressing to clinical disease, as well as for advancing the development of a formal biomarker qualification plan to support future studies on neurofilament and its role in FTD. This progress lays the groundwork for enhancing early detection and accelerating research efforts in neurodegenerative diseases. IDENTIFYING RISK OF PROGRESSION TO MULTIPLE MYELOMA: MMYERISK Multiple myeloma, a cancer of plasma cells, is almost always preceded by asymptomatic, pre-malignant conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Although these precursor conditions are common, most patients do not progress to multiple myeloma. MMyeRisk, launched in 2024, seeks to identify which patients are likely to progress and identify those likely to benefit from early therapeutic intervention. The project team expects to achieve these aims through validation of blood-based genomic methods to define tumor and immune biomarkers. EVALUATING IMMUNOTHERAPY TREATMENT RESPONSE: IRELATE Despite the potential of immunotherapy, only a minority of patients respond to treatment. As effective immunotherapy treatments enhance T-cell infiltration and activation, understanding T-cell behavior is paramount for developing successful treatment strategies. Biopsies are used to assess T-cell states, but they are invasive and may not accurately reflect tumor burden. Positron emission tomography (PET) imaging holds promise as a non-invasive, comprehensive means for evaluating T-cell activity. The iRelate project aims to assess T-cell presence and activation state using two PET ligands in clinical development. Using both PET tracers will enable characterization of tracer uptake in tumor tissue and T cell-rich organs and is expected to provide information on unique and additive capacities of these tracers. This work is intended to serve as a foundation for defining potential context of use for PET biomarkers and to support the development and selection of successful immunotherapy treatment strategies. |
| Form 990, Part III, Line 4a Program Service Description | RESEARCH PROGRAMS FOR ADVANCING GLOBAL HEALTH A-PLUS: ANTIBIOTIC PROVES COST EFFECTIVE IN REDUCING MATERNAL INFECTIONS A 2023 international trial, supported in part by the FNIH, revealed that one dose of the oral antibiotic azithromycin during labor can greatly reduce maternal sepsis or death in low- and middle-income countries. For this work, the research team won top honors from the Clinical Research Forum in 2024. Two analyses published in 2024 using data from that trial, the Azithromycin Prevention in Labor Use Study (A-PLUS), assessed possible additional benefits of this strategy to prevent infections, which account for approximately 11% of maternal deaths worldwide. One of the two recent studies showed that any maternal infection, including sepsis, abscesses, and wound infections, occurred 29% less often when the drug was administered during labor. The second study, which modeled the benefits and costs of intrapartum azithromycin, showed a reduction in hospital readmissions, unplanned clinical visits, and use of additional antibiotics. Using the average health-care costs across the study's eight clinical sites, the savings was estimated at $32,661 per 100,000 pregnancies. STRENGTHENING THE PATIENT VOICE Patients are at the heart of the FNIH mission, and their voices are incorporated into our research programs. People with lived experiences, patient advocacy groups, and care providers are vital to our work, helping to ensure that our programs look holistically at the impact our research will have on health and well-being. The FNIH's patient engagement strategy - including the Patient Ambassadors and Patient Engagement Council - reflects our commitment to ensuring patient voices guide our work. Their insights are essential to shaping impactful, forward-looking research programs. |
| Form 990, Part III, Line 4b Program Service Description | PROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - POWERING SCIENCE: 2024 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCES The Lurie Prize recognized outstanding achievement by promising scientists aged 52 years old or younger. The award included a $100,000 honorarium. PAUL-GALLIN TRAILBLAZER PRIZE FOR PHYSICIAN-SCIENTISTS The Paul-Gallin Trailblazer Prize recognizes the outstanding contributions of early- to mid-career physician-scientists whose research translates basic discoveries into novel approaches for diagnosing, preventing, treating, or curing disease and disability. The award includes a $100,000 honorarium. CHARLES A. SANDERS, MD, PARTNERSHIP AWARD We recognize our partners and their contributions through the annual Charles A. Sanders, MD, Partnership Award. This prize recognizes persons and/or organizations that have made significant contributions to our work in creating, implementing, and nurturing public-private partnerships that build bridges to breakthroughs in improved therapeutics, diagnostics, and potential cures. KOVLER PRIZE FOR TRUST IN LIFE SCIENCE JOURNALISM The Kovler Prize, which debuted in 2024 and carries a $25,000 honorarium, recognizes individual reporters who make complex health- and science-related topics digestible for the public. EVENTS AND EDUCATION In collaboration with the NIH and generous donors and partners, the FNIH manages training initiatives that offer educational opportunities to science students, ranging from high school to post-doctoral scholars, crossing boundaries and cultures. They learn through intensive training, collaborative engagement, mentoring, and hands-on research. Legacy funds from individual benefactors and foundations help move scientific achievement farther, faster, and give hope to future patients. Individual programs provide financial support, mentoring, and recognition to promising young scientists. Here is a just a sample of how the FNIH and its supporters power science: - The Deeda Blair Research Initiative for Disorders of the Brain awarded in 2024 three promising early-career physician-scientists with bold approaches to address mental illness. Each awardee received $200,000. This initiative was established by Mrs. William McCormick Blair, Jr., a member of the FNIH Board of Directors. - The Medical Research Scholars Program is a one-year intensive training program on the NIH campus offering medical, dental, and veterinary students opportunities to become engaged in research early in their careers. The FNIH has supported a total of 572 scholars since the program was established. - The FNIH promotes emerging research from up-and-coming scientists through annual lectures co-sponsored by the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the National Institute of Allergy and Infectious Diseases, the National Center for Complementary and Integrative Health, and elsewhere. - For a complete list of all the ways the FNIH is powering science, go to the FNIH website. |
| Form 990, Part VI, Line 15a & 15b - Process to Establish Compensation | The Compensation Committee of the Board reviewed and concurred with the CEO's decisions establishing and adjusting the senior executive team's annual salaries and related compensation decisions. The Compensation Committee also approved the compensation level of the CEO and related compensation decisions. This process is undertaken annually. |
| Form 990, Part VI, Line 1a Delegate broad authority to a committee | The Board has an Executive Committee, which can make decisions on behalf of the Board (with some exceptions) between board meetings. |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | The Form 990 is prepared and reviewed by an independent accounting firm. Prior to the submission of the Foundation for NIH's Form 990 to the Internal Revenue Service, each voting member of the board of directors shall be provided with a copy of the draft Form 990 as approved by the Chief Financial Officer. |
| Form 990, Part VI, Line 12c Conflict of interest policy | Directors, officers and employees are required to annually sign a statement which affirms that they have: - Received a copy of the conflict of interest policy - Read, understood and agreed to comply with the policy - Received and reviewed a listing of corporate and foundation donors, contractors, vendors, grantees, principal investigators and financial institutions with whom the FNIH has a current relationship - No actual or apparent conflicts of interest other than those disclosed in the statement. They must also make certain notifications in particular circumstances. The conflict of interest policy also has mechanisms for handling such conflicts. |
| Form 990, Part VI, Line 19 Required documents available to the public | All such documents are available upon request. In addition, the governing documents and financial statements are available on the FNIH website. |
| Form 990, Part X, Column (B) Cash & Investments | Approximately $122 Million of FNIH's Cash and Investments are invested in high quality short-term fixed income securities which are committed to FNIH's restricted assets. |
| Form 990, Part XI, Line 9 Other changes in net assets or fund balances | Refund of Prior Year Grants - 654801; Total - 654801; |
| Software ID: | 24020961 |
| Software Version: | 2024v5.1 |